Spots Global Cancer Trial Database for stage iii
Every month we try and update this database with for stage iii cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Trial for Large ER-Negative Breast Cancers | NCT01869192 | Malignant Neopl... | Epirubicin Cyclophosphamid... Docetaxel Capecitabine Radiation Thera... | 18 Years - | University of Colorado, Denver | |
| Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery | NCT02391194 | Breast Cancer | AVB-620 | 18 Years - | Avelas Biosciences, Inc. | |
| Adjuvant Aspirin Treatment for Colon Cancer Patients | NCT02467582 | Colon Cancer | Aspirin Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | NCT00960115 | Non-small Cell ... | Tecemotide (L-B... Single low dose... Placebo Saline | 20 Years - | Merck KGaA, Darmstadt, Germany | |
| Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung | NCT03589547 | Stage III Non-s... | Durvalumab SBRT | 18 Years - | Brown University | |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | NCT02288897 | Cutaneous Melan... | PV-10 (10% rose... Dacarbazine, te... | 18 Years - | Provectus Pharmaceuticals | |
| Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | NCT01318642 | Adenocarcinoma ... Locally Advance... Unresectable | Gemcitabine AMG 479 Placebo | 18 Years - | Amgen | |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | NCT06056310 | Head and Neck C... | Xevinapant Cisplatin intensity-modul... | 18 Years - | EMD Serono | |
| Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma | NCT01456104 | Melanoma | Langerhans-type... | - | Memorial Sloan Kettering Cancer Center | |
| Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | NCT02810743 | Breast Cancer | ddAC-CP-Olapari... ddAC-mini CTC | 18 Years - 65 Years | The Netherlands Cancer Institute | |
| Fecal Microbiota Transplant (FMT) in Melanoma Patients | NCT03341143 | Melanoma | Fecal Microbiot... | 18 Years - | University of Pittsburgh | |
| Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer | NCT06086574 | Lung Cancer Sta... | 18 Years - | University of Manchester | ||
| Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer | NCT00426257 | Ovarian Cancer | Secondary debul... secondary debul... | 18 Years - 76 Years | The Netherlands Cancer Institute | |
| Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | NCT04995094 | Pathologic Stag... | Imprime PGG Pembrolizumab | 18 Years - | HiberCell, Inc. | |
| Cisplatin + RT for Triple Negative Breast Cancer | NCT01674842 | Breast Cancer | Radiation Thera... Cisplatin | 18 Years - | Dana-Farber Cancer Institute | |
| CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | NCT00710892 | Acute Lymphobla... Non-Hodgkin's L... Myelodysplastic... Chronic Myeloid... | Allodepleted T ... | - 65 Years | Baylor College of Medicine | |
| Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC | NCT04765709 | Non-small Cell ... | durvalumab plus... Durvalumab plus... durvalumab | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | NCT03311308 | Advanced Melano... | Pembrolizumab I... Metformin | 18 Years - | University of Pittsburgh | |
| Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma | NCT01883323 | Metastatic, Sta... | Cyclophosphamid... Fludarabine Tumor-Infiltrat... Low-Dose Interl... | 18 Years - | University Health Network, Toronto | |
| Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer | NCT00078390 | Non Small Cell ... Lung Cancer Stage IIIA Non ... Stage IIIB Non ... | S-3304 Chemo-irradiati... | 18 Years - 85 Years | Shionogi Inc. | |
| Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca | NCT00756132 | Locally Advance... Breast Cancer | 18 Years - 65 Years | University Health Network, Toronto | ||
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | NCT01551693 | Melanoma | STA-9090 | 18 Years - | Dana-Farber Cancer Institute | |
| External ValidatIon Trial of ASTER Trial | NCT01332240 | Stage III Lung ... | Endoscopic ultr... | 18 Years - 95 Years | Universitaire Ziekenhuizen KU Leuven | |
| A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT02412371 | Non-small Cell ... | Paclitaxel Placebo for Vel... Carboplatin Veliparib Radiotherapy | 18 Years - | AbbVie | |
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | NCT05386550 | Head and Neck C... | Xevinapant (Deb... IMRT Placebo | 18 Years - | EMD Serono | |
| Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux | NCT00609284 | HNSCC | cetuximab Carboplatin, 5F... Radiotherapy | 18 Years - 70 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Fecal Microbiota Transplant (FMT) in Melanoma Patients | NCT03341143 | Melanoma | Fecal Microbiot... | 18 Years - | University of Pittsburgh | |
| Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients | NCT00774839 | Colon Cancer | Patient Intervi... | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients | NCT00774839 | Colon Cancer | Patient Intervi... | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer | NCT04865705 | Stage III Non-small Cell ... | tislelizumab | 18 Years - 65 Years | West China Hospital | |
| Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases | NCT01114958 | Lung Neoplasms Neoplasm Metast... | Cisplatin, Thio... | 18 Years - | University of California, San Diego | |
| Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca | NCT00787488 | Ovarian Cancer | Hyperthermia | 18 Years - 72 Years | Duke University | |
| Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab | NCT05027165 | Oncology Biomarker NSCLC, Stage II... Durvalumab Chemoradiothera... | Non-interventio... | 18 Years - | LMU Klinikum | |
| Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | NCT02810743 | Breast Cancer | ddAC-CP-Olapari... ddAC-mini CTC | 18 Years - 65 Years | The Netherlands Cancer Institute | |
| Improving Goals of Care Discussion in Advanced Cancer Patients | NCT02374255 | Primary Stage I... Esophageal Colorectal Canc... Glioblastoma Cancer of Stoma... Cancer of Pancr... Melanoma Head or Neck Ca... Stage III Stage IV Lung Cancers Pancreatic Canc... | GoC interventio... | 21 Years - | Icahn School of Medicine at Mount Sinai | |
| Rectal Cancer Consortium | NCT01835925 | Rectal Cancer | Tissue specimen | 18 Years - | Brown University | |
| A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer | NCT00001193 | Breast Neoplasm... Neoplasm Metast... | high dose melph... | - | National Institutes of Health Clinical Center (CC) | |
| External ValidatIon Trial of ASTER Trial | NCT01332240 | Stage III Lung ... | Endoscopic ultr... | 18 Years - 95 Years | Universitaire Ziekenhuizen KU Leuven | |
| Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy | NCT05031975 | Colorectal Canc... | Irinotecan Temozolomide | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer | NCT04865705 | Stage III Non-small Cell ... | tislelizumab | 18 Years - 65 Years | West China Hospital | |
| Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma | NCT01456104 | Melanoma | Langerhans-type... | - | Memorial Sloan Kettering Cancer Center | |
| Minimal SN Tumor Burden | NCT01942603 | Cutaneous Melan... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | ||
| Rectal Cancer Consortium | NCT01835925 | Rectal Cancer | Tissue specimen | 18 Years - | Brown University | |
| Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer | NCT01565772 | Non-Small Cell ... | Proton Beam Rad... Cisplatin Etoposide | 18 Years - | Massachusetts General Hospital | |
| Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls" | NCT03071809 | Neoplasms, Non-... | 18 Years - | Lexent Bio, Inc. | ||
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | NCT05386550 | Head and Neck C... | Xevinapant (Deb... IMRT Placebo | 18 Years - | EMD Serono | |
| Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00002774 | Squamous Neck C... | Tirapazamine Cisplatin 5-fluorouracil Radiotherapy (R... | 17 Years - | Stanford University | |
| Minimal SN Tumor Burden | NCT01942603 | Cutaneous Melan... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | ||
| BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study | NCT02550743 | Rectal Cancer | BYL719 Capecitabine Radiation | 18 Years - | Brown University | |
| Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | NCT05352672 | Melanoma | Fianlimab Cemiplimab Pembrolizumab Placebo | 12 Years - | Regeneron Pharmaceuticals | |
| T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy | NCT02250209 | Gastric Cancer | Trastuzumab Capecitabine Oxaliplatin | 18 Years - 80 Years | Chinese PLA General Hospital | |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | NCT05174169 | Stage III Colon... | Signatera test mFOLFOX6 3-6 mo... CAPOX 3 month mFOLFIRINOX mFOLFOX6 6 mont... CAPOX 6 month | 18 Years - | NRG Oncology | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | NCT06056310 | Head and Neck C... | Xevinapant Cisplatin intensity-modul... | 18 Years - | EMD Serono | |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | NCT03053193 | Breast Cancer | MammaPrint, Blu... | 18 Years - | Agendia | |
| Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer | NCT01322802 | Stage III Ovari... Stage III Ovari... Stage IV Ovaria... Stage IV Ovaria... | pUMVC3-hIGFBP-2... laboratory biom... | 18 Years - | University of Washington | |
| Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) | NCT04389177 | Esophageal Squa... Stage III | Pembrolizumab I... | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC | NCT03822351 | Stage III Non-s... Unresectable | Durvalumab + Ol... Durvalumab Durvalumab + Mo... | 18 Years - 99 Years | MedImmune LLC | |
| A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer | NCT00001193 | Breast Neoplasm... Neoplasm Metast... | high dose melph... | - | National Institutes of Health Clinical Center (CC) | |
| Prebiotics in Rectal Cancer | NCT05516641 | Rectal Cancer | Soluble Corn Fi... Maltodextrin | 18 Years - | Ochsner Health System | |
| INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | NCT04203511 | Non-small Cell ... | Retifanlimab Placebo Pemetrexed Cisplatin Carboplatin Paclitaxel Etoposide Radiotherapy | 18 Years - | Incyte Corporation | |
| CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | NCT00710892 | Acute Lymphobla... Non-Hodgkin's L... Myelodysplastic... Chronic Myeloid... | Allodepleted T ... | - 65 Years | Baylor College of Medicine | |
| Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer | NCT01565772 | Non-Small Cell ... | Proton Beam Rad... Cisplatin Etoposide | 18 Years - | Massachusetts General Hospital | |
| Phase II Trial for Large ER-Negative Breast Cancers | NCT01869192 | Malignant Neopl... | Epirubicin Cyclophosphamid... Docetaxel Capecitabine Radiation Thera... | 18 Years - | University of Colorado, Denver | |
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | NCT01551693 | Melanoma | STA-9090 | 18 Years - | Dana-Farber Cancer Institute | |
| Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02) | NCT00881712 | Non-Small Cell ... | PET positive no... PET positive no... Patients consid... | 18 Years - | University of Florida | |
| Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases | NCT01114958 | Lung Neoplasms Neoplasm Metast... | Cisplatin, Thio... | 18 Years - | University of California, San Diego | |
| A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | NCT05608291 | Melanoma | Fianlimab Cemiplimab Pembrolizumab Placebo | 12 Years - | Regeneron Pharmaceuticals | |
| Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | NCT04792073 | Merkel Cell Car... | Avelumab Comprehensive A... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer | NCT02664077 | Stage III (IIIB... | Regorafenib Placebo | 18 Years - | NSABP Foundation Inc | |
| Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) | NCT03241927 | Melanoma | Pembrolizumab | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | NCT03311308 | Advanced Melano... | Pembrolizumab I... Metformin | 18 Years - | University of Pittsburgh | |
| Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer | NCT01218594 | Non-small Cell ... | Endostatin | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients | NCT00774839 | Colon Cancer | Patient Intervi... | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab. | NCT04381494 | Unresectable St... | Multiparametric... | 18 Years - 130 Years | AstraZeneca | |
| A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy | NCT05178576 | Colon Cancer | Gevokizumab Signatera test | 18 Years - | NSABP Foundation Inc | |
| Rectal Cancer Consortium | NCT01835925 | Rectal Cancer | Tissue specimen | 18 Years - | Brown University | |
| Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy | NCT05031975 | Colorectal Canc... | Irinotecan Temozolomide | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
